| Scrip Code | 544319 |
|---|---|
| NSE Symbol | SENORES |
| MSEI Symbol | NOTLISTED |
| ISIN | INE0RB801010 |
| Name of company | SENORES PHARMACEUTICALS LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 27-07-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 21-07-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Single segment |
| Description of single segment | Pharmaceuticals |
| Start date and time of board meeting | 27-07-2026 13:45:00 |
| End date and time of board meeting | 27-07-2026 14:55:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | Yes |
| No. of times funds raised during the quarter | 2 |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| Not applicable for quarter ended June 30, 2026 | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 2,699.00 | 2,699.00 | |
| Other income | 955.00 | 955.00 | |
| Total income | 3,654.00 | 3,654.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 747.00 | 747.00 |
| (b) | Purchases of stock-in-trade | 419.00 | 419.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 49.00 | 49.00 |
| (d) | Employee benefit expense | 1,010.00 | 1,010.00 |
| (e) | Finance costs | 222.00 | 222.00 |
| (f) | Depreciation, depletion and amortisation expense | 361.00 | 361.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 707.00 | 707.00 |
| Total other expenses | 707.00 | 707.00 | |
| Total expenses | 3,515.00 | 3,515.00 | |
| 3 | Total profit before exceptional items and tax | 139.00 | 139.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 139.00 | 139.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 31.00 | 31.00 |
| 8 | Deferred tax | 5.00 | 5.00 |
| 9 | Total tax expenses | 36.00 | 36.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 103.00 | 103.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 103.00 | 103.00 |
| 17 | Other comprehensive income net of taxes | 0.00 | 0.00 |
| 18 | Total Comprehensive Income for the period | 103.00 | 103.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 4,605.00 | 4,605.00 | |
| Face value of equity share capital | 10 | 10 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 0.22 | 0.22 | |
| Diluted earnings (loss) per share from continuing operations | 0.22 | 0.22 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 0.22 | 0.22 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 0.22 | 0.22 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | ||
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| Total Amount of items that will not be reclassified to profit and loss | |||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0.00 | 0.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | 0.00 | 0.00 |
| Mode of Fund Raising | Public Issues |
|---|---|
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 26-12-2024 |
| Amount Raised | 50,000.00 |
| Report filed for Quarter ended | 30-06-2026 |
| Monitoring Agency | Applicable |
| Monitoring Agency Name, if applicable | CARE Ratings Limited |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | |
| If Yes, Date of shareholder Approval | |
| Explanation for the Deviation / Variation | Not Applicable |
| Comments of the Audit Committee after review | No Comments |
| Comments of the auditors, if any | No Comments |
| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1 | Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility | Not applicable | 10,700.00 | 0.00 | 698.00 | 0.00 | There is on-going delay in deployment of funds under object-1. Now, the company has sought shareholder approval for variation in the objects / terms of utilisation of IPO proceeds and extension of time limit through postal ballot. |
| 2 | Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company | Not applicable | 7,348.00 | 7,310.00 | 7,310.00 | 0.00 | The unutilized amount of Rs. 0.38 crore has been transferred to GCP as resolved in the Board Meeting dated July 23, 2025. |
| 3 | Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries | Not applicable | 2,022.00 | 2,020.00 | 2,020.00 | 0.00 | The unutilized amount of Rs. 0.02 crore has been transferred to GCP as resolved in the Board Meeting dated July 23, 2025. |
| 4 | Funding the working capital requirements of our Company | Not applicable | 4,326.00 | 0.00 | 4,326.00 | 0.00 | |
| 5 | Investment in our Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements | Not applicable | 5,948.00 | 0.00 | 5,948.00 | 0.00 | |
| 6 | Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes | Not applicable | 15,437.00 | 16,191.00 | 16,163.00 | 0.00 | Amount of Rs. 7.54 crore has been transferred from Objective 2, 3 and 7. |
| 7 | Offer expenses | Not applicable | 4,219.00 | 3,504.00 | 3,480.00 | 0.00 | The unutilized amount of Rs. 6.31 crore under objective-7 has been transferred to objective-6 as resolved in the Board Meeting dt. March 28, 2026 and Rs. 0.84 crore as resolved in Board Meeting dt. May 14. 2026 |
| Mode of Fund Raising | Preferential Issues |
|---|---|
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 28-03-2026 |
| Amount Raised | 9,500.00 |
| Report filed for Quarter ended | 30-06-2026 |
| Monitoring Agency | Not Applicable |
| Monitoring Agency Name, if applicable | |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | |
| If Yes, Date of shareholder Approval | |
| Explanation for the Deviation / Variation | false |
| Comments of the Audit Committee after review | No Comments |
| Comments of the auditors, if any | No Comments |
| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1 | Funding the working capital requirements of our Company | Not Applicable | 3,125.00 | 0.00 | 684.00 | 0.00 | |
| 2 | Funding the product development expenditure for the Company | Not Applicable | 2,500.00 | 0.00 | 0.00 | 0.00 | |
| 3 | Investment in our subsidiaries, by way of loan, to fund their working capital requirements | Not Applicable | 1,500.00 | 0.00 | 615.00 | 0.00 | |
| 4 | General Corporate Purpose | Not Applicable | 2,375.00 | 0.00 | 392.00 | 0.00 |
| Name of signatory | Deval Rajnikant Shah |
| Designation of person | Chief Financial Officer |
| Place | Ahmedabad |
| Date | 27-07-2026 |